IS2980B - Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl - Google Patents

Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl

Info

Publication number
IS2980B
IS2980B IS7621A IS7621A IS2980B IS 2980 B IS2980 B IS 2980B IS 7621 A IS7621 A IS 7621A IS 7621 A IS7621 A IS 7621A IS 2980 B IS2980 B IS 2980B
Authority
IS
Iceland
Prior art keywords
amino
cyanoethyl
benzonitrile
dimethylphenyl
pyrimidinyl
Prior art date
Application number
IS7621A
Other languages
English (en)
Icelandic (is)
Other versions
IS7621A (is
Inventor
Philippe Robert Schils Didier
Josephus Maria Willems Joannes
Petrus Anna Maria Jozef Medaer Bart
Therese Jeanne Pasquier Elisabeth
Adriaan Jan Janssen Paul
Heeres Jan
Gerardus George Leenders Ruben
Emile Georges Guillemont Jérome
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31725448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2980(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of IS7621A publication Critical patent/IS7621A/is
Publication of IS2980B publication Critical patent/IS2980B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/20—Preparation of carboxylic acid nitriles by dehydration of carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IS7621A 2002-08-09 2004-12-29 Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl IS2980B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078306 2002-08-09
PCT/EP2003/050366 WO2004016581A1 (en) 2002-08-09 2003-08-07 Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Publications (2)

Publication Number Publication Date
IS7621A IS7621A (is) 2004-12-29
IS2980B true IS2980B (is) 2017-09-15

Family

ID=31725448

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7621A IS2980B (is) 2002-08-09 2004-12-29 Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl

Country Status (25)

Country Link
US (3) US7399856B2 (de)
EP (1) EP1529032B1 (de)
JP (1) JP4822707B2 (de)
KR (2) KR101086678B1 (de)
CN (4) CN102702111B (de)
AR (1) AR040964A1 (de)
AU (1) AU2003266413B2 (de)
CA (2) CA2493794C (de)
CL (1) CL2010000284A1 (de)
CY (1) CY1114428T1 (de)
DK (1) DK1529032T3 (de)
EA (1) EA007953B1 (de)
ES (1) ES2422196T3 (de)
HR (1) HRP20050104B1 (de)
IL (1) IL166710A (de)
IS (1) IS2980B (de)
MX (1) MXPA05001541A (de)
MY (1) MY144894A (de)
NO (1) NO330013B1 (de)
NZ (1) NZ538611A (de)
PL (1) PL208533B1 (de)
PT (1) PT1529032E (de)
SI (1) SI1529032T1 (de)
TW (1) TWI314146B (de)
WO (1) WO2004016581A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
WO2005123662A1 (en) * 2004-06-18 2005-12-29 Janssen Pharmaceutica N.V. Modified heck reaction
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
MX2007002594A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
DK1632232T6 (da) * 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
UA92467C2 (ru) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
US7314962B2 (en) * 2005-04-15 2008-01-01 E. I. Du Pont De Nemours & Co. Alkylation of aromatic compounds
ES2437202T3 (es) * 2005-05-26 2014-01-09 Janssen R&D Ireland Procedimiento para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)-amino]benzonitrilo
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
US8426434B2 (en) * 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2643294B1 (de) * 2011-04-15 2016-08-24 Emcure Pharmaceuticals Limited Verbessertes rilpivirinverfahren
EP2702044B1 (de) 2011-04-25 2017-03-22 Hetero Research Foundation Verfahren für rilpivirin
EP2755959B1 (de) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirin-hydrochlorid
WO2013170421A1 (zh) * 2012-05-14 2013-11-21 上海迪赛诺药业有限公司 利匹韦林盐酸盐醇化物多晶型物及其制备方法
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
WO2014009968A2 (en) * 2012-07-12 2014-01-16 Hetero Research Foundation Process for rilpivirine using novel intermediate
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
RS65159B1 (sr) 2016-10-24 2024-02-29 Janssen Sciences Ireland Unlimited Co Disperzibilni sastavi
US20210380540A1 (en) 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
EP0002341B1 (de) 1977-11-28 1982-01-20 Barry Boettcher Zweiwertige Kupferkomplexe, Verfahren zu deren Herstellung und solche Komplexe enthaltende Zusammensetzungen
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
AU751573C (en) * 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
JP2000035628A (ja) 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
JP3635238B2 (ja) * 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
AU759875B2 (en) 1999-03-09 2003-05-01 Pharmacia & Upjohn Company 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7276510B2 (en) * 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CN1494528A (zh) 2001-03-02 2004-05-05 ʷ��˿�������ȳ�ķ���޹�˾ 作为逆转录酶抑制剂的二苯酮
ES2292753T4 (es) * 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PL220850B1 (pl) * 2002-05-03 2016-01-29 Janssen Pharmaceutica Nv Kopolimer dwublokowy, kompozycja zawierająca składnik aktywny i jej zastosowanie oraz sposób jej wytwarzania
CN102702111B (zh) * 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Also Published As

Publication number Publication date
CN100554245C (zh) 2009-10-28
AU2003266413A1 (en) 2004-03-03
KR101086678B1 (ko) 2011-11-25
BR0313545B1 (pt) 2021-07-27
PL373679A1 (en) 2005-09-05
HK1081527A1 (en) 2006-05-19
MY144894A (en) 2011-11-30
IL166710A0 (en) 2006-01-15
CA2493794A1 (en) 2004-02-26
NO330013B1 (no) 2011-02-07
EP1529032A1 (de) 2005-05-11
IS7621A (is) 2004-12-29
AU2003266413B2 (en) 2009-04-02
HK1174922A1 (en) 2013-06-21
CA2686429A1 (en) 2004-02-26
EA200500325A1 (ru) 2005-06-30
PL208533B1 (pl) 2011-05-31
EA007953B1 (ru) 2007-02-27
CN102702111A (zh) 2012-10-03
TWI314146B (en) 2009-09-01
JP4822707B2 (ja) 2011-11-24
CA2686429C (en) 2010-11-16
CN101481356A (zh) 2009-07-15
JP2005537303A (ja) 2005-12-08
MXPA05001541A (es) 2005-04-19
US20070191407A1 (en) 2007-08-16
US7563922B2 (en) 2009-07-21
IL166710A (en) 2010-12-30
KR101140785B1 (ko) 2012-05-03
DK1529032T3 (da) 2013-07-08
HRP20050104B1 (hr) 2014-02-14
CN102702111B (zh) 2014-12-17
CA2493794C (en) 2010-05-25
US20080167464A1 (en) 2008-07-10
TW200418810A (en) 2004-10-01
SI1529032T1 (sl) 2013-08-30
KR20050040906A (ko) 2005-05-03
EP1529032B1 (de) 2013-04-24
HK1129671A1 (en) 2009-12-04
CN102225902A (zh) 2011-10-26
US7705148B2 (en) 2010-04-27
HRP20050104A2 (en) 2006-03-31
CY1114428T1 (el) 2016-08-31
BR0313545A (pt) 2005-07-12
KR20100127889A (ko) 2010-12-06
NO20050524L (no) 2005-02-01
PT1529032E (pt) 2013-07-11
WO2004016581A1 (en) 2004-02-26
US7399856B2 (en) 2008-07-15
CN102225902B (zh) 2013-04-24
US20060167253A1 (en) 2006-07-27
CL2010000284A1 (es) 2010-08-20
ES2422196T3 (es) 2013-09-09
AR040964A1 (es) 2005-04-27
HK1161869A1 (en) 2012-08-10
CN101481356B (zh) 2012-07-11
NZ538611A (en) 2007-03-30
CN1681774A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
IS7621A (is) Aðferðir til þess að búa til 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pyrimidínýl]amínó]bensónítríl
LTC1632232I2 (lt) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
DK2175857T3 (da) Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
DK1610780T3 (da) Cykliske protein-tyrosin-kinasehæmmere
IS8425A (is) Hámörkuð tjáning af HPV 58 L1 í gersveppi
EP1534268A4 (de) Tyrosin-kinase-hemmer
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
DE602004028739D1 (de) Metabolit von quetiapine
DK1578731T3 (da) Fremgangsmåde til fremstilling af pyrimidinforbindelser
ATE381541T1 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
CR9031A (es) Clorhidrato de 4-((4-((4-2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino)benzonitrilo
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
AP2487A (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
DK1419160T3 (da) Fremgangsmåde til fremstilling af 6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-eddikesyre
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
DK1569695T3 (da) Antisense-modulering af apolipoprotein-b-ekspression
ITRM20010736A1 (it) Impianto osteointegrato di lunghezza aggiustabile e un kit per la suapreparazione.
UA7546S (uk) Готова страва, що складається з двох компонентів